This paper introduces the reader to the field of liquid biopsies and cell-free nucleic acids,
focusing on circulating tumor DNA (ctDNA) in breast cancer (BC). BC is the most common …

Both breast cancer and obesity can regulate epigenetic changes or be regulated by
epigenetic changes. Due to the well-established link between obesity and an increased risk …

Despite their promise, circulating tumor DNA (ctDNA)-based assays for multi-cancer early
detection face challenges in test performance, due mostly to the limited abundance of ctDNA …

Cancer is the second most common cause of death in children aged 1–14 years in the
United States, with 11,000 new cases and 1200 deaths annually. Pediatric cancers typically …

The emergence of multicancer early detection (MCED) tests holds promise for improving
early cancer detection and public health outcomes. However, positive MCED test results …

In current clinical practice, effective cancer testing and screening paradigms are limited to
specific types of cancer, exhibiting varying efficiency, acceptance, and adherence. Cell-free …

Liquid biopsy for minimally invasive diagnosis and monitoring of cancer patients is
progressing toward routine clinical practice. With the implementation of highly sensitive next …

This review provides a comprehensive overview of the latest advancements in the clinical
utility of liquid biopsy, with a particular focus on epigenetic approaches aimed at overcoming …

Background The emergence of multi-cancer early detection (MCED) via a single blood test
offers promise in enhancing the efficiency of early cancer detection and improving …

Abstract Background Cell free DNA (cfDNA)-based assays hold great potential in detecting
early cancer signals yet determining the tissue-of-origin (TOO) for cancer signals remains a …